Evidence map›Paper›PMID 25971334›Full record

ArticleOncotarget2015

Destabilisation of dimeric 14-3-3 proteins as a novel approach to anti-cancer therapeutics.

Joanna M Woodcock, Carl Coolen, Katy L Goodwin, Dong Jae Baek, Robert Bittman, Michael S Samuel, Stuart M Pitson, Angel F Lopez

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. The 14-3-3 Proteins as Important Allosteric Regulators of Protein Kinases.International journal of molecular sciences · 2020
    Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Joanna M WoodcockCentre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA, Australia.
Carl CoolenCentre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA, Australia.
Katy L GoodwinCentre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA, Australia.
Dong Jae BaekDepartment of Chemistry and Biochemistry, Queens College of the City University of New York, Flushing, NY, USA.
Robert BittmanDepartment of Chemistry and Biochemistry, Queens College of the City University of New York, Flushing, NY, USA.
Michael S SamuelCentre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA, Australia.
Stuart M PitsonCentre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA, Australia.
Angel F LopezCentre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA, Australia.
South Australia Pathology · AUCentre for Cancer Biology · AUQueens College, CUNY · USUniversity of South Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

14-3-3 proteins play a pivotal role in controlling cell proliferation and survival, two commonly dysregulated hallmarks of cancers. 14-3-3 protein expression is enhanced in many human cancers and correlates with more aggressive tumors and poor prognosis, suggesting a role for 14-3-3 proteins in tumorigenesis and/or progression. We showed previously that the dimeric state of 14-3-3 proteins is regulated by the lipid sphingosine, a physiological inducer of apoptosis. As the functions of 14-3-3 proteins are dependent on their dimeric state, this sphingosine-mediated 14-3-3 regulation provides a possible means to target dimeric 14-3-3 for therapeutic effect. However, sphingosine mimics are needed that are not susceptible to sphingolipid metabolism. We show here the identification and optimization of sphingosine mimetics that render dimeric 14-3-3 susceptible to phosphorylation at a site buried in the dimer interface and induce mitochondrial-mediated apoptosis. Two such compounds, RB-011 and RB-012, disrupt 14-3-3 dimers at low micromolar concentrations and induce rapid down-regulation of Raf-MAPK and PI3K-Akt signaling in Jurkat cells. Importantly, both RB-011 and RB-012 induce apoptosis of human A549 lung cancer cells and RB-012, through disruption of MAPK signaling, reduces xenograft growth in mice. Thus, these compounds provide proof-of-principle for this novel 14-3-3-targeting approach for anti-cancer drug discovery.

Indexed as

14-3-3 ProteinsAnimalsApoptosisHumansJurkat CellsLung NeoplasmsMicePhosphorylationSignal TransductionSphingosine14-3-3 ProteinsSphingosineapoptosisbiochemistrysignal transductionsmall moleculessphingosine

Identifiers

PMID25971334
PMCPMC4546484
OpenAlexW1875650818

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.